Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics
←Back to story

US FDA approves at-home use of BioXcel's agitation drug | Reuters

ReutersView source article

Part of story

FDA approves at-home use of BioXcel's agitation drug Igalmi

The FDA approved at-home use of BioXcel Therapeutics' Igalmi (dexmedetomidine) for agitation associated with schizophrenia or bipolar disorder, expanding access beyond clinical settings.

Nov 16, 2026·2 sourcesFDA drug approvalMental Health & WellbeingDrug Policy, Pricing & ApprovalPsychosis & schizophrenia spectrum
FDA approves at-home use of BioXcel's agitation drug Igalmi
00

Other sources for this story

Medscape

US FDA Approves At-home Use Of BioXcel's Agitation Drug